Full Breakdown
FTC Sues Hims & Hers Over Health-Data Sharing, Billing and Subscription Practices
7/30/2026, 1:08:04 AM
Core Allegations and Legal Action
On July 29, the U.S. Federal Trade Commission filed a lawsuit in the Northern District of California, joined by Los Angeles County and the states of Utah and California. The complaint accuses telehealth provider Hims & Hers Health, Inc. of:
- Transmitting users’ sensitive health information to online advertising platforms, specifically Meta Platforms and Snap, through tracking technologies embedded on its website.
- Charging customers for prescription drugs before they have spoken with a healthcare provider, often immediately after completing an intake form.
- Making it difficult for consumers to cancel recurring subscription plans, burying cancellation options behind multi-step menus and requiring notice as short as two days before a refill charge that is processed up to ten days early.
Background & Context
Hims & Hers, a direct-to-consumer telehealth company with more than two million subscribers, offers virtual appointments and ships prescriptions for weight-loss drugs, erectile dysfunction, hair loss and mental-health medications. The FTC’s investigation dates back to October 2023, and a 2025 probe examined the firm’s advertising and cancellation practices.
Data & Statistics
- Stock reaction: Market reports indicated the shares fell roughly 12 % after the filing (Independent, Reuters, CNBC). TradingView cited a 13 % decline, creating a minor discrepancy.
- Financial exposure: In May, Hims & Hers disclosed a $15 million probable-loss accrual related to the FTC investigation, warning that the final cost could be higher.
- Revenue outlook: The firm reported $2.35 billion in revenue for 2025 and projects $2.8-$3 billion for 2026.
- Consumer complaints: The complaint cites a patient charged $897 for a prescription before any clinician contact, and another billed $147 for a three-month supply of Lexapro after merely indicating openness to medication on an intake form.
Official Statements & Responses
The company added that it has made a settlement offer without admitting wrongdoing and will “vigorously defend” its position.
Why It Matters
The case highlights growing regulatory scrutiny of telehealth platforms that blend medical services with digital advertising. If the FTC’s claims are upheld, the company could face significant penalties under the FTC Act and the Restore Online Shoppers’ Confidence Act, and it may be forced to redesign its data-sharing and billing workflows. The lawsuit also raises broader questions about consumer privacy in the rapidly expanding virtual-care market, potentially prompting tighter oversight of how health data are monetized.
Conflicting Reports & Gaps
- Stock-price impact: Most outlets (Independent, Reuters, CNBC) report a ?12 % drop, while TradingView records a 13 % decline.
- Scope of data sharing: The complaint lists Meta, Snap, Google and TikTok as recipients, but some sources mention only Meta and Snap. Further clarification from the FTC filing would resolve this variance.
Verbatim Quotes
- “The FTC will not hesitate to act on behalf of consumers deprived of their ability to choose which products they want and whether to keep their most sensitive health information private.” — Director, of the FTC’s Bureau of Consumer Protection
What’s Next
The company is scheduled to report its second-quarter results after the market close on August 10. The outcome of that earnings release may reflect any financial adjustments stemming from the FTC action.
